Impact Factor
2.85
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.76
313 total citations
h5-index
17
h5 depth signal
Cited share
53.8%
99 of 184
Total citations
313
Citation footprint
Metric signal
1.98
External metric anchor
Self-citation
1.0%
3 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
143
China
114
Israel
78
Italy
64
Japan
52
Citing Fields of Research
Hematology
677
Lymphomas
232
Immunology
75
Oncology
62
Auto-Inflammatory Disorders
34
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
8,309
Articles tracked across the journal lifetime
Indexed publication set
184
99 cited publications
Last 12 months
63
5.3 publications/month
Open access share
30.2%
19 OA publications in the last year
Leading citing country
United States
143 citing publications
Leading citing field
Hematology
677 citing publications
Latest tracked publication
10 October 2026
10 recent records available
Coverage & Indexing History
v34n1,Jul. 1965-
v34n1,Jul. 1965-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Hematology
Issuing & Sponsoring Bodies
Contributor
European Society of Haematology
Contributor
International European Society of Hematology
Contributor
International Society of Hematology. European Division
Broad Categories
Hematology
Lymphomas
MeSH Descriptors
Hematology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1159/aha/abkag006
Open DOI
Clinical Features and Prognostic Impact of Splicing Factor Mutations and Their Co-Mutations in Acute Myeloid Leukemia
Introduction: The clinical and prognostic significance of splicing factor (SF) mutations in newly diagnosed adult de novo acute myeloid leukemia (AML) remains incompletely defined. This study aimed to characterize the clinical features, ...
02
DOI 10.1159/aha/abkag007
Open DOI
Lactoferrin as a Natural Modulator of Immunity and Iron Homeostasis: A Review of Current Knowledge
Background: Lactoferrin is an iron-binding glycoprotein found in secretions and neutrophil granules that regulates iron availability in conjunction with host defense. Furthermore, it modulates innate and adaptive immune responses and aff...
03
DOI 10.1159/aha/abkag015
Open DOI
Oral Versus Intravenous Hypomethylating Agents in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multicenter Real-World Toxicity Comparison
Background: Hypomethylating agents (HMAs) are a cornerstone of therapy for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Oral formulations offer an alternative to intravenous (IV) administration, but comparative real-...
04
DOI 10.1159/aha/abkag002
Open DOI
Navigating the Immune Landscape: Balancing Efficacy and Toxicity of B-Cell Maturation Antigen-Targeting Agents in Multiple Myeloma
Background: Multiple myeloma is a plasma cell malignancy with a complex genomic landscape, and relapse remains common despite therapeutic advances. B-cell maturation antigen (BCMA), selectively expressed on malignant plasma cells, has em...
05
DOI 10.1159/aha/abkag004
Open DOI
Global Disparities in Multiple Myeloma Quality of Care Indicators and Their Association with Socioeconomic Development and Behavioral Risk Factors: An Analysis of GBD 2021 Data
Introduction: The aim of the study was to analyze global quality of multiple myeloma (MM) care and factors associated with its variation using the Quality of Care Index (QCI). Methods: Data were obtained from the Global Burden of Disease...
06
DOI 10.1159/aha/abkag014
Open DOI
Post-Marketing Safety of the Menin Inhibitor Revumenib: A Bayesian Disproportionality Analysis of a National Database
Background Revumenib is a first-in-class oral inhibitor of the menin–KMT2A protein–protein interaction, approved by the United States Food and Drug Administration in November 2024 for relapsed or refractory acute leukemia with a KMT2A tr...
07
DOI 10.1159/aha/abkag012
Open DOI
Helicobacter pylori in Haematology: Contextualising Established and Emerging Associations
08
DOI 10.1159/000553020
Open DOI
The Prevalence and Clinical Impact of Bone Marrow Fibrosis in Chronic Myeloid Leukemia
Introduction: Bone marrow fibrosis may be present at chronic myeloid leukemia (CML) diagnosis and has been historically associated with poorer treatment responses. Its prognostic value is unclear for clinical outcomes in the current tyro...
09
DOI 10.1159/aha/abkag011
Open DOI
Impact of Helicobacter pylori infection on severe hematologic disorders
10
DOI 10.1159/aha/abkag013
Open DOI
T-Cell Leukemia Cell Line Harboring Previously Undescribed CBFB::MYL11 Fusion Exhibits a Genome Profile Implicating Cytoskeletal Abnormality
Introduction: Gene fusions involving core binding factors (CBFs), such as CBFB::MYH11, are major contributing factors to leukemia development. The pathogenic mechanism is believed to lie in abnormalities in CBF, however, myosin, the fusi...
Bibliographical & Catalog Notes
Also available online.
Articles in English, French or German, with summaries in all three languages.
Official organ of the société internationale européene d'hématologie, 1950-June 1951; of the Société européene d'hématologie, July 1951-1967 (no. 2/3); of the European Division of the International Society of Haematology, 1967 (no. 5/6)-
Indexes: Every 5th vol. includes a five year cumulative index.
Vol. 87, no. 1 (1992)19921001 Notice published Printed on acid-free paper